Skip to Main Content

COVID-19 is an emerging, rapidly evolving situation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.nih.gov/coronavirus

Data were also collected on whether cancers progressed after initial treatment. For participants with confirmed lung cancer, medical records were retrieved periodically after diagnosis and treatment to determine whether the lung cancer had progressed. A data collection form was filled out for each follow-up period (one-half year for ACRIN, one year for LSS) after diagnosis, with each form recording instances of progression that began during that follow-up period.

Progression was defined as enlargement of the original tumor, new metastasis to lymph nodes or other organ site not included in the original tumor staging, or disease recurrence. Death was not considered disease progression.

Lung cancer progression data is included in the Participant dataset.

Summary Available Data
  • Data collected annually or semi-annually after diagnosis of lung cancer
  • ~4700 forms from ~1500 cancers
  • ~800 forms indicated progression in ~500 participants
  • Data were collected on the following forms:
  • Whether progression occurred after treatment
  • Days from randomization to first documentation of progression
  • Site(s) of progression